The nonsteroidal mineralocorticoid receptor antagonist finerenone has been shown to reduce the risks of major clinical kidney and cardiovascular outcomes in individuals with chronic kidney disease ...
The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27. Finerenone—a selective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results